Cachexia - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 59 pages report, published by Global Markets Direct

Keywords : Cachexia Therapeutic Products under Development, Key Players in Cachexia Therapeutics, Cachexia Pipeline Overview, Cachexia Pipeline, Cachexia Pipeline Assessment

Report ThumbnailSeptember-2013
Cachexia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Cachexia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cachexia. Cachexia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cachexia.
- A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cachexia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cachexia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Cachexia, H2 2013 8
  • Products under Development for Cachexia - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Discovery and Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 28
  • Assessment by Route of Administration, H2 2013 29
  • Assessment by Stage and Route of Administration, H2 2013 30
  • Assessment by Molecule Type, H2 2013 31
  • Assessment by Stage and Molecule Type, H2 2013 32
  • List of Tables
  • Number of Products Under Development for Cachexia, H2 2013 8
  • Products under Development for Cachexia - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 11
  • Number of Products under Investigation by Universities/Institutes, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • GlaxoSmithKline plc, H2 2013 18
  • Plexxikon Inc., H2 2013 19
  • BioLineRx, Ltd., H2 2013 20
  • Novartis AG, H2 2013 21
  • Aphios Corporation, H2 2013 22
  • Calzada Limited, H2 2013 23
  • Palatin Technologies, Inc., H2 2013 24
  • Cytokinetics, Inc, H2 2013 25
  • Fate Therapeutics, Inc., H2 2013 26
  • Rhythm Pharmaceuticals, H2 2013 27
  • Assessment by Monotherapy Products, H2 2013 28
  • Assessment by Stage and Route of Administration, H2 2013 30
  • Assessment by Stage and Molecule Type, H2 2013 32
  • Cachexia Therapeutics - Drug Profile Updates 47
  • Cachexia Therapeutics - Discontinued Products 49
  • Cachexia Therapeutics - Dormant Products 50
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Cachexia Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Cachexia 8
  • Cachexia Therapeutics under Development by Companies 10
  • Cachexia Therapeutics under Investigation by Universities/Institutes 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Discovery and Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Cachexia Therapeutics - Products under Development by Companies 16
  • Cachexia Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Cachexia Therapeutics Development 18
  • GlaxoSmithKline plc 18
  • Plexxikon Inc. 19
  • BioLineRx, Ltd. 20
  • Novartis AG 21
  • Aphios Corporation 22
  • Calzada Limited 23
  • Palatin Technologies, Inc. 24
  • Cytokinetics, Inc 25
  • Fate Therapeutics, Inc. 26
  • Rhythm Pharmaceuticals 27
  • Cachexia - Therapeutics Assessment 28
  • Assessment by Monotherapy Products 28
  • Assessment by Route of Administration 29
  • Assessment by Molecule Type 31
  • Drug Profiles 33
  • RM-131 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • BL-5040 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • dronabinol - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • CK-2066260 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • FT-301 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • bimagrumab - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Drug For Cachexia - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • PLX-4720 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • GSK-2849466 - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • FB-704 - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • Activin Antagonists - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • Cachexia Therapeutics - Drug Profile Updates 47
  • Cachexia Therapeutics - Discontinued Products 49
  • Cachexia Therapeutics - Dormant Products 50
  • Cachexia - Product Development Milestones 51
  • Featured News & Press Releases 51
  • Apr 01, 2013: Cytokinetics Initiates Phase I Clinical Trial Of CK-2127107 51
  • Jan 03, 2013: Alize Pharma Launches PREMAG Research Program 51
  • Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix 52
  • Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 53
  • Jan 09, 2012: Ohr Pharmaceutical Receives US And European Composition Of Matter Patents 54
  • Sep 12, 2011: XBiotech Provides Early Results From True Human Antibody Therapy Clinical Study In Cachexia 54
  • Jul 20, 2011: Galapagos Initiates Proof-of-Mechanism Clinical Study Of Candidate Cachexia Drug GLPG0492 55
  • Dec 27, 2010: Vicus Initiates Phase II Trial To Evaluate VT-122 In Patients With Liver Cancer Receiving Nexavar 55
  • Dec 02, 2010: Galapagos Successfully Completes First-In-Human Trial Of GLPG0492 In Cachexia Patients 56
  • Jul 30, 2010: Formatech To Provide Services To Formulate And Fill Femta's FM101 Under Fillanthropy Program 57
  • Appendix 58
  • Methodology 58
  • Coverage 58
  • Secondary Research 58
  • Primary Research 58
  • Expert Panel Validation 58
  • Contact Us 59
  • Disclaimer 59

Please select a license type

Share

Related Products

Global Markets DirectCachexia - Pipeline Review, H2 2013Product ThumbnailCachexia - Pipeline Review, H2 2013, Industry ReportProduct #: 113300
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved